Medicus Pharma Ltd.

Medicus Pharma Ltd. announced it has regained compliance with Nasdaq's minimum bid price requirement of $1.00. The company had previously received a delisting determination letter after failing to meet the requirement by October 19, 2026, and was not eligible for an extension. However, the closing bid price has been at or above $1.00 for the past ten consecutive business days, leading Nasdaq to close the matter. The company cautioned that there is no assurance it will maintain future compliance.

Medicus Pharma Ltd. reported a significant widening of its net loss for both the three and six months ended June 30, 2026, reaching $11.68 million and $20.73 million, respectively. The company's shareholders' equity turned into a deficit of $1.72 million, reflecting substantial accumulated losses. Despite the worsening operational performance, Medicus Pharma successfully raised considerable capital through equity offerings and debentures, leading to a notable increase in total assets and cash, but also a corresponding rise in total liabilities.

Medicus Pharma Ltd. announced the appointment of Faisal Mehmud, MD, MRCP, as Chief Executive Officer of its UK subsidiary, Antev Limited, effective August 30, 2026. Dr. Mehmud will also continue in his roles as Chief Medical Officer of Medicus and Co-Chairman of Antev. This strategic appointment aims to strengthen the company's leadership as it advances the global development of Teverelix® across multiple indications. Dr. Mehmud, with over 20 years of global pharmaceutical experience, succeeds Amit Kohli, who served as interim CEO of Antev for one year following its acquisition.

Medicus Pharma Ltd. announced that the UAE Department of Health – Abu Dhabi granted Investigational New Drug (IND) authorization for its PRECISION-E2 Phase 2a clinical study. This study will evaluate Teverelix® in approximately 84 women with moderate-to-severe symptomatic endometriosis, marking a significant regulatory milestone for the company's women's health strategy. The study is designed as a genomics-guided precision medicine program to identify patients most likely to benefit from the long-acting GnRH antagonist.

Medicus Pharma Ltd. announced that the U.S. Food and Drug Administration (FDA) has issued a "Study May Proceed" letter for its Investigational New Drug (IND) application for SKNJCT-005. This authorization allows the company to initiate a registrational Phase 2b clinical study evaluating SkinJect® (D-MNA) 200 mcg in patients with Gorlin Syndrome presenting with multiple basal cell carcinomas. The FDA's recommendations are expected to strengthen the study's scientific rigor and support long-term evaluation of treatment durability, positioning SkinJect® for a robust data package toward a potential NDA submission.

Medicus Pharma Ltd. announced its participation in the 2026 Bio International Conference, where Chief Medical Officer Dr. Faisal Mehmud will present updates on the company's clinical, regulatory, and strategic advancements. The presentation will highlight positive Phase 2 results for SkinJect® in basal cell carcinoma, ongoing FDA interactions, and regulatory initiatives for Gorlin Syndrome. Additionally, updates on Teverelix® will include progress in advanced prostate cancer, acute urinary retention relapse, and the newly initiated PRECISION-E2 Phase 2a study for endometriosis.

Medicus Pharma Ltd. announced the submission of a Rare Pediatric Disease Designation (RPDD) request to the U.S. FDA for SkinJect®, its investigational doxorubicin-containing microneedle array patch, for treating basal cell carcinoma in patients with Gorlin Syndrome. This follows a previous Orphan Drug Designation application and positive Phase 2 study results showing 64% clinical clearance and 55% complete response. If granted, RPDD could lead to a Priority Review Voucher, potentially accelerating FDA review, and Orphan Drug Designation could provide seven years of market exclusivity, addressing a significant unmet medical need for this rare disease.

Medicus Pharma Ltd. announced the submission of an Investigational New Drug (IND) application to the Department of Health, Abu Dhabi, for PRECISION-E2, a Phase 2a genomics-enabled clinical trial. This study will evaluate Teverelix® in approximately 84 women with symptomatic endometriosis in the United Arab Emirates, leveraging the Emirati Genome Program. The trial aims to develop a personalized treatment model for endometriosis by combining clinical, hormonal, pharmacokinetic, and genomic data, potentially transforming the management of estrogen-driven diseases.

Medicus Pharma Ltd. held its 2026 Annual General and Special Meeting of Shareholders on June 3, 2026. Shareholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the 2026 fiscal year. All nine directors nominated by the Board were elected to serve one-year terms. Additionally, shareholders approved a special resolution authorizing the Board to effect a common share consolidation at a ratio up to 50-to-1, if deemed necessary or desirable.

Medicus Pharma Ltd. announced it has entered into a definitive financing agreement with an institutional investor for an up to $22 million structured financing facility. This financing is expected to boost the company's pro forma cash position to approximately $30 million, providing a projected operating cash runway of over twenty-four months. The company will receive $12 million immediately, with an additional $10 million released upon achieving specified milestones, and intends to use the proceeds to advance clinical development programs, pursue strategic initiatives, and repay existing debt.